Mesa Laboratories, Inc.
NASDAQ:MLABHardware, Equipment & Parts
-$0.15 today
- Market cap
- $774.56M
- Beta
- 0.93
- P/E (TTM)
- 78.3
- EPS (TTM)
- $1.21
- Dividend yield
- 0.68%
Volume 0.07M
Average 0.16M
MLAB EBITDA Margin
EBITDA as a percentage of revenue.
Mesa Laboratories, Inc.NASDAQ: MLAB
EBITDA Margin · Q4 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 6.5%
EBITDA Margin was 6.5% in Q4 FY2026, down 10.3 pp from a year earlier. On a trailing-twelve-month basis it was 17.4%, up 0.1 pp year over year. Over 3 fiscal years it narrowed by 3.0 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 43.5% for the fiscal year ending Mar 2027, up from 14.2% in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 6.5%-14.0 pp QoQ
- Last fiscal yearMar 2026
- 14.2%-3.4 pp YoY
- LTMMar 2026
- 17.4%+0.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.3 pp | +19.1 pp | +29.5 pp |
| 1 year | -3.4 pp | +29.4 pp | +32.8 pp |
| 3 years | -3.0 pp | — | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2026
- 14.2%
- Year-over-year change
- -3.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 14.2% | -3.4pp |
| FY2025 | 2025-03-31 | 17.6% | +127.8pp |
| FY2024 | 2024-03-31 | -110.3% | -127.4pp |
| FY2023 | 2023-03-31 | 17.1% | -0.5pp |
| FY2022 | 2022-03-31 | 17.6% | — |
EBITDA Margin vs competitors
How MLAB compares with its peers on the latest reported figures
- MLAB's LTM Mar 2026 EBITDA Margin of 17.4% is the 7th highest of the 11 companies compared; the peer median is 21.8%.
- Its year-over-year change of +0.1 pp is the 6th highest of 11, against a peer median of -0.2 pp.
- Over three fiscal years its change of -3.0 pp compares with a peer median of -1.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 33.5% | -1.6 pp | -2.1 pp | |
| LTM Jul 2026 | 27.6% | +1.1 pp | -1.4 pp | |
| LTM Sep 2026 | 26.8% | +8.6 pp | -11.9 pp | |
| LTM Jul 2026 | 26.3% | -3.0 pp | -8.9 pp | |
| LTM Sep 2026 | 23.7% | -2.2 pp | -0.9 pp | |
| LTM Jun 2026 | 19.9% | -6.2 pp | +208.5 pp | |
| LTM Mar 2026 | 17.4% | +0.1 pp | -3.0 pp | |
| LTM Sep 2026 | 6.1% | +10.9 pp | +25.5 pp | |
| LTM Jun 2026 | -26.6% | +89.9 pp | -148.5 pp | |
| LTM Mar 2026 | -66.6% | +85.7 pp | +198.6 pp | |
| LTM Mar 2026 | -94.5% | -30.2 pp | +72.1 pp | |
| Peer median (excluding MLAB) | 21.8% | -0.2 pp | -1.1 pp | |
Competitors are the stored peer set for MLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 184.34M | 219.08M | 216.19M | 240.98M | 249.13M |
| Cost of Revenue | 75.25M | 85.39M | 82.94M | 90.11M | 90.86M |
| Gross Profit | 109.09M | 133.69M | 133.25M | 150.87M | 158.27M |
| Gross Margin | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| Research & Development | 15.77M | 20.49M | 19.3M | 19.52M | 20.31M |
| Selling, General & Admin | 88.62M | 109.88M | 111.49M | 115.02M | 119.45M |
| Operating Expenses | 104.39M | 130.37M | 405.33M | 134.53M | 139.76M |
| Depreciation & Amortization | 25.07M | 33.13M | 31.57M | 24.53M | 23.27M |
| EBITDA | 32.53M | 37.52M | (238.38M) | 42.35M | 35.29M |
| EBITDA Margin | 17.6% | 17.1% | -110.3% | 17.6% | 14.2% |
| Operating Income | 4.7M | 3.32M | (272.08M) | 16.34M | 18.51M |
| Operating Margin | 2.6% | 1.5% | -125.9% | 6.8% | 7.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.89M | 4.77M | 5.7M | 11.86M | 10.69M |
| Other Income / Expenses | (1.13M) | (3.71M) | (3.57M) | (10.38M) | (6.5M) |
| Income Before Tax | 3.57M | (389K) | (275.65M) | 5.96M | 12.01M |
| Pre-Tax Margin | 1.9% | -0.2% | -127.5% | 2.5% | 4.8% |
| Income Tax Expense | 1.7M | (1.32M) | (21.4M) | 7.94M | 5.3M |
| Net Income | 1.87M | 930K | (254.25M) | (1.97M) | 6.71M |
| Net Margin | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% |
| EPS (Basic) | 0.36 | 0.17 | (47.20) | (0.36) | 1.22 |
| EPS (Diluted) | 0.35 | 0.17 | (47.20) | (0.36) | 1.21 |
| Weighted Avg Shares | 5.21M | 5.32M | 5.39M | 5.43M | 5.51M |
| Weighted Avg Shares (Diluted) | 5.34M | 5.36M | 5.39M | 5.43M | 5.57M |
Mesa Laboratories, Inc.
NASDAQ:MLAB
Intrinsic Alpha fair value
Locked
Current Price
$137.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.